---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-010404"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:16:49.597347+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics names Harout Semerjian CEO to succeed retiring Rachel King; Q2 cash $118.9M

## Summary
- CEO Rachel King retires effective Aug 6, 2021; remains on board and as consultant. Harout Semerjian appointed CEO effective Aug 6.
- New CEO receives $595K salary, $200K sign-on bonus, target bonus 55%, and stock options for ~1.65M shares with milestone-based vesting.
- As of June 30, 2021, cash and equivalents $118.9M (down from $137.0M at Dec 31, 2020); Q2 R&D $10.2M, G&A $4.2M.
- Enrollment in Phase 3 relapsed/refractory AML trial and NCI Phase 2/3 trial expected to complete by year-end 2021.
- Compensation Committee increased Inducement Plan shares from 500K to 2M; grants to new CEO from this plan.

## SEC filing metadata
- accession: 0001558370-21-010404
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/0001558370-21-010404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/glyc-20210730x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-010404
- JSON: https://secwatch.observer/filing/0001558370-21-010404.json
- Plain text: https://secwatch.observer/filing/0001558370-21-010404.txt

## Key facts
- Executive change
  Harout Semerjian was appointed as President and Chief Executive Officer at CRESCENT BIOPHARMA, INC..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On August 2, 2021, the Board appointed Harout Semerjian as the Company’s President and Chief Executive Officer, effective as of August 6, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/0001558370-21-010404-index.htm
- Executive change
  Rachel K. King retired as President and Chief Executive Officer at CRESCENT BIOPHARMA, INC..
  - Action: retired
  - Role: President and Chief Executive Officer
  source text: On July 30, 2021, Rachel K. King, President and Chief Executive Officer of the Company, notified the Board of Directors of the Company (the “ Board ”) of her decision to retire from those positions, effective as of August 6, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837021010404/0001558370-21-010404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.